Synthesis of [11C] N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′-methylguanidine ([11C]GMOM): a candidate PET tracer for imaging the PCP site of the NMDA ion channel

The N‐methyl‐D‐aspartate (NMDA) ion channel plays an important role in a number of neurodegenerative disorders including stroke, Parkinson's disease, Huntington's Chorea, Alzheimer's disease, schizophrenia and epilepsy. To provide effective radioligands for imaging the PCP binding sit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of labelled compounds & radiopharmaceuticals 2002-10, Vol.45 (11), p.955-964
Main Authors: Waterhouse, Rikki N., Dumont, Filip, Sultana, Abida, Simpson, Norman, Laruelle, Marc
Format: Article
Language:English
Subjects:
Biological and medical sciences
Contrast media. Radiopharmaceuticals
glutamate
Medical sciences
NMDA
PET
Pharmacology. Drug treatments
phencyclidine
radiotracer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3312-3296d4421fb70750290082ae642384508e6587208ae8aa74509b8ebe13975e473
cites cdi_FETCH-LOGICAL-c3312-3296d4421fb70750290082ae642384508e6587208ae8aa74509b8ebe13975e473
container_end_page 964
container_issue 11
container_start_page 955
container_title Journal of labelled compounds & radiopharmaceuticals
container_volume 45
creator Waterhouse, Rikki N.
Dumont, Filip
Sultana, Abida
Simpson, Norman
Laruelle, Marc
description The N‐methyl‐D‐aspartate (NMDA) ion channel plays an important role in a number of neurodegenerative disorders including stroke, Parkinson's disease, Huntington's Chorea, Alzheimer's disease, schizophrenia and epilepsy. To provide effective radioligands for imaging the PCP binding site of the NMDA ion channel, we synthesized and characterized in vitro the candidate PCP site ligand N‐(2‐chloro‐5‐thiomethylphenyl)‐N′‐(3‐methoxyphenyl)‐N′‐methylguanidine (GMOM: Ki = 5.2 ± 0.3 nM, log P = 2.34). The corresponding PET radiotracer [11C]GMOM was synthesized with a radiochemical yield of 8.4 ± 3.2% EOS and with a specific activity of 1.23 ± 0.25 Ci/μmol EOS (n = 5). The average time required for synthesis, purification and formulation was 52 ± 5 min. The final product was prepared in a sterile saline solution suitable for in vivo use. Copyright © 2002 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/jlcr.622
format article
fullrecord <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jlcr_622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_ZFMX84MK_M</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3312-3296d4421fb70750290082ae642384508e6587208ae8aa74509b8ebe13975e473</originalsourceid><addsrcrecordid>eNp1kM1u1DAYRS1EJYYWiUfwBmm6cPFfYoddFdrhZzIdQREIhCyPx5m4TZ2RnarNjmeib9QnwUMqEAtWlu93dHR1AXhO8BHBmL68aE04yil9BCYEFwUijPPHYIJZThGXmD0BT2O8wDjdOJ-Au4-D7xsbXYRdDb8RUn6HCzSlyDRtFzqUob5x3ZXtm6HdNtYP7SFa3P_4iaYM7dLudvgnHsnNtfZu7byF09_KWXVWHb6CGhrt126tewuXJ-ewD9rYAOsuQHelN85vYOoCl-USRpeY1Gj3X1Svj6HrPDSN9t62B2Cv1m20zx7effDp9OS8fIPmZ7O35fEcGcYIRYwW-ZpzSuqVwCLDtMBYUm1zTpnkGZY2z6SgWGortRYpKVbSrixhhcgsF2wfTEevCV2MwdZqG1LPMCiC1W5stRtbpbET-mJEtzoa3dZBe-PiX54VMhe4SBwauRvX2uG_PvVuXn4YvQ-8i729_cPrcKlywUSmPi9m6utp9UXy6r2q2C_1wZxv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Synthesis of [11C] N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′-methylguanidine ([11C]GMOM): a candidate PET tracer for imaging the PCP site of the NMDA ion channel</title><source>Wiley</source><creator>Waterhouse, Rikki N. ; Dumont, Filip ; Sultana, Abida ; Simpson, Norman ; Laruelle, Marc</creator><creatorcontrib>Waterhouse, Rikki N. ; Dumont, Filip ; Sultana, Abida ; Simpson, Norman ; Laruelle, Marc</creatorcontrib><description>The N‐methyl‐D‐aspartate (NMDA) ion channel plays an important role in a number of neurodegenerative disorders including stroke, Parkinson's disease, Huntington's Chorea, Alzheimer's disease, schizophrenia and epilepsy. To provide effective radioligands for imaging the PCP binding site of the NMDA ion channel, we synthesized and characterized in vitro the candidate PCP site ligand N‐(2‐chloro‐5‐thiomethylphenyl)‐N′‐(3‐methoxyphenyl)‐N′‐methylguanidine (GMOM: Ki = 5.2 ± 0.3 nM, log P = 2.34). The corresponding PET radiotracer [11C]GMOM was synthesized with a radiochemical yield of 8.4 ± 3.2% EOS and with a specific activity of 1.23 ± 0.25 Ci/μmol EOS (n = 5). The average time required for synthesis, purification and formulation was 52 ± 5 min. The final product was prepared in a sterile saline solution suitable for in vivo use. Copyright © 2002 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0362-4803</identifier><identifier>EISSN: 1099-1344</identifier><identifier>DOI: 10.1002/jlcr.622</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Biological and medical sciences ; Contrast media. Radiopharmaceuticals ; glutamate ; Medical sciences ; NMDA ; PET ; Pharmacology. Drug treatments ; phencyclidine ; radiotracer</subject><ispartof>Journal of labelled compounds &amp; radiopharmaceuticals, 2002-10, Vol.45 (11), p.955-964</ispartof><rights>Copyright © 2002 John Wiley &amp; Sons, Ltd.</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3312-3296d4421fb70750290082ae642384508e6587208ae8aa74509b8ebe13975e473</citedby><cites>FETCH-LOGICAL-c3312-3296d4421fb70750290082ae642384508e6587208ae8aa74509b8ebe13975e473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13986709$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Waterhouse, Rikki N.</creatorcontrib><creatorcontrib>Dumont, Filip</creatorcontrib><creatorcontrib>Sultana, Abida</creatorcontrib><creatorcontrib>Simpson, Norman</creatorcontrib><creatorcontrib>Laruelle, Marc</creatorcontrib><title>Synthesis of [11C] N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′-methylguanidine ([11C]GMOM): a candidate PET tracer for imaging the PCP site of the NMDA ion channel</title><title>Journal of labelled compounds &amp; radiopharmaceuticals</title><addtitle>J Label Compd Radiopharm</addtitle><description>The N‐methyl‐D‐aspartate (NMDA) ion channel plays an important role in a number of neurodegenerative disorders including stroke, Parkinson's disease, Huntington's Chorea, Alzheimer's disease, schizophrenia and epilepsy. To provide effective radioligands for imaging the PCP binding site of the NMDA ion channel, we synthesized and characterized in vitro the candidate PCP site ligand N‐(2‐chloro‐5‐thiomethylphenyl)‐N′‐(3‐methoxyphenyl)‐N′‐methylguanidine (GMOM: Ki = 5.2 ± 0.3 nM, log P = 2.34). The corresponding PET radiotracer [11C]GMOM was synthesized with a radiochemical yield of 8.4 ± 3.2% EOS and with a specific activity of 1.23 ± 0.25 Ci/μmol EOS (n = 5). The average time required for synthesis, purification and formulation was 52 ± 5 min. The final product was prepared in a sterile saline solution suitable for in vivo use. Copyright © 2002 John Wiley &amp; Sons, Ltd.</description><subject>Biological and medical sciences</subject><subject>Contrast media. Radiopharmaceuticals</subject><subject>glutamate</subject><subject>Medical sciences</subject><subject>NMDA</subject><subject>PET</subject><subject>Pharmacology. Drug treatments</subject><subject>phencyclidine</subject><subject>radiotracer</subject><issn>0362-4803</issn><issn>1099-1344</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNp1kM1u1DAYRS1EJYYWiUfwBmm6cPFfYoddFdrhZzIdQREIhCyPx5m4TZ2RnarNjmeib9QnwUMqEAtWlu93dHR1AXhO8BHBmL68aE04yil9BCYEFwUijPPHYIJZThGXmD0BT2O8wDjdOJ-Au4-D7xsbXYRdDb8RUn6HCzSlyDRtFzqUob5x3ZXtm6HdNtYP7SFa3P_4iaYM7dLudvgnHsnNtfZu7byF09_KWXVWHb6CGhrt126tewuXJ-ewD9rYAOsuQHelN85vYOoCl-USRpeY1Gj3X1Svj6HrPDSN9t62B2Cv1m20zx7effDp9OS8fIPmZ7O35fEcGcYIRYwW-ZpzSuqVwCLDtMBYUm1zTpnkGZY2z6SgWGortRYpKVbSrixhhcgsF2wfTEevCV2MwdZqG1LPMCiC1W5stRtbpbET-mJEtzoa3dZBe-PiX54VMhe4SBwauRvX2uG_PvVuXn4YvQ-8i729_cPrcKlywUSmPi9m6utp9UXy6r2q2C_1wZxv</recordid><startdate>20021015</startdate><enddate>20021015</enddate><creator>Waterhouse, Rikki N.</creator><creator>Dumont, Filip</creator><creator>Sultana, Abida</creator><creator>Simpson, Norman</creator><creator>Laruelle, Marc</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20021015</creationdate><title>Synthesis of [11C] N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′-methylguanidine ([11C]GMOM): a candidate PET tracer for imaging the PCP site of the NMDA ion channel</title><author>Waterhouse, Rikki N. ; Dumont, Filip ; Sultana, Abida ; Simpson, Norman ; Laruelle, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3312-3296d4421fb70750290082ae642384508e6587208ae8aa74509b8ebe13975e473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Contrast media. Radiopharmaceuticals</topic><topic>glutamate</topic><topic>Medical sciences</topic><topic>NMDA</topic><topic>PET</topic><topic>Pharmacology. Drug treatments</topic><topic>phencyclidine</topic><topic>radiotracer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Waterhouse, Rikki N.</creatorcontrib><creatorcontrib>Dumont, Filip</creatorcontrib><creatorcontrib>Sultana, Abida</creatorcontrib><creatorcontrib>Simpson, Norman</creatorcontrib><creatorcontrib>Laruelle, Marc</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><jtitle>Journal of labelled compounds &amp; radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Waterhouse, Rikki N.</au><au>Dumont, Filip</au><au>Sultana, Abida</au><au>Simpson, Norman</au><au>Laruelle, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis of [11C] N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′-methylguanidine ([11C]GMOM): a candidate PET tracer for imaging the PCP site of the NMDA ion channel</atitle><jtitle>Journal of labelled compounds &amp; radiopharmaceuticals</jtitle><addtitle>J Label Compd Radiopharm</addtitle><date>2002-10-15</date><risdate>2002</risdate><volume>45</volume><issue>11</issue><spage>955</spage><epage>964</epage><pages>955-964</pages><issn>0362-4803</issn><eissn>1099-1344</eissn><abstract>The N‐methyl‐D‐aspartate (NMDA) ion channel plays an important role in a number of neurodegenerative disorders including stroke, Parkinson's disease, Huntington's Chorea, Alzheimer's disease, schizophrenia and epilepsy. To provide effective radioligands for imaging the PCP binding site of the NMDA ion channel, we synthesized and characterized in vitro the candidate PCP site ligand N‐(2‐chloro‐5‐thiomethylphenyl)‐N′‐(3‐methoxyphenyl)‐N′‐methylguanidine (GMOM: Ki = 5.2 ± 0.3 nM, log P = 2.34). The corresponding PET radiotracer [11C]GMOM was synthesized with a radiochemical yield of 8.4 ± 3.2% EOS and with a specific activity of 1.23 ± 0.25 Ci/μmol EOS (n = 5). The average time required for synthesis, purification and formulation was 52 ± 5 min. The final product was prepared in a sterile saline solution suitable for in vivo use. Copyright © 2002 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><doi>10.1002/jlcr.622</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0362-4803
ispartof Journal of labelled compounds & radiopharmaceuticals, 2002-10, Vol.45 (11), p.955-964
issn 0362-4803
1099-1344
language eng
recordid cdi_crossref_primary_10_1002_jlcr_622
source Wiley
subjects Biological and medical sciences
Contrast media. Radiopharmaceuticals
glutamate
Medical sciences
NMDA
PET
Pharmacology. Drug treatments
phencyclidine
radiotracer
title Synthesis of [11C] N-(2-chloro-5-thiomethylphenyl)-N′-(3-methoxyphenyl)-N′-methylguanidine ([11C]GMOM): a candidate PET tracer for imaging the PCP site of the NMDA ion channel
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A38%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20of%20%5B11C%5D%20N-(2-chloro-5-thiomethylphenyl)-N%E2%80%B2-(3-methoxyphenyl)-N%E2%80%B2-methylguanidine%20(%5B11C%5DGMOM):%20a%20candidate%20PET%20tracer%20for%20imaging%20the%20PCP%20site%20of%20the%20NMDA%20ion%20channel&rft.jtitle=Journal%20of%20labelled%20compounds%20&%20radiopharmaceuticals&rft.au=Waterhouse,%20Rikki%20N.&rft.date=2002-10-15&rft.volume=45&rft.issue=11&rft.spage=955&rft.epage=964&rft.pages=955-964&rft.issn=0362-4803&rft.eissn=1099-1344&rft_id=info:doi/10.1002/jlcr.622&rft_dat=%3Cistex_cross%3Eark_67375_WNG_ZFMX84MK_M%3C/istex_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3312-3296d4421fb70750290082ae642384508e6587208ae8aa74509b8ebe13975e473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true